Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Antti Kangas)

Nightingale Health Plc Company release 18 June 2024 at 3:20 p.m. (EEST)   Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Antti Kangas’s ownership of shares exceeds 5 % of all shares and votes exceed 20 % of all votes in Nightingale Health. Antti Kangas’s ownership and votes exceeded the notification threshold before April 19, 2024. The notification of exceeding the ownership and voting right threshold is retroactive because an amendment to the

Vår Energi ASA: Notification of trade by primary insider

Sandnes, Norway, 18 June 2024: Deputy employee representative to the Board, Trond Arvid Larsen in Vår Energi (OSE: VAR) has bought 2000 shares in the company at a price of NOK 34.3 per share. Following the purchase, Larsen holds a total of 10 550 shares in Vår Energi. This information is subject to the disclosure requirements pursuant to MAR article 19 and Section 5-12 the Norwegian Securities Trading Act. Contact Investor relations Ida Marie Fjellheim, Head of Investor Relations +47 90509291 ida.fjellheim@varenergi.no About Vår Energi Vår Energi is a leading

STENOCARE A/S: Notice for deadline of trading TO2 Warrants

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO Stenocare TO2 Warrant trading will end close of business June 19. To benefit from the discounted share price of DKK 3.16 each, subscribers need to own TO2 Warrants (ticker: STENO TO2).Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. These warrants can be purchased and/or sold until the deadline of June 19, 2024, at 17:00 Central European Summer Time. The TO2 Warrants can be used to subscribe to (purchase) the new Stenocare shares at a discounted price of DKK 3.16 each during

SOFTSWISS Game Aggregator Unveils Game Release Calendar

The SOFTSWISS Game Aggregator, a leading content hub for iGaming projects , launched a Game Release Calendar designed to enhance operators' convenience and operational efficiency.The Game Release Calendar provides operators with a weekly preview of upcoming game releases. It offers advance information about new providers joining the platform and anticipated new games from existing ones. This helps operators decide which games to acquire and plan their activities more effectively.

DanCann Pharma A/S: Solid growth in the Rx portfolio

COPENHAGEN, Denmark, 18 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides an update on its current portfolio and expectations for the year ahead.Key highlights from the portfolio[1] and pipeline[2]: · Growth in 2023: Achieved a sales growth of +40% year-over-year (YoY) in pharmacy sales. · Sales volume: This growth equated to +14,000 packages of medicine. · 2024 projections: The Company aims to further increase the current Rx portfolio sales volume to 20,000 packages in 2024, representing a

ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine

Hørsholm, Denmark, 18 June 2024 – ExpreS2ion Biotech Holding AB’s ("ExpreS2ion" or the "Company") (NASDAQ First North: EXPRS2) announces that its recent webinar covering the 2024 rights issue, hosted by CEO Bent Frandsen and CFO Keith Alexander, is now available for on-demand viewing. The webinar  provided insights into the background and rationale for the rights issue, detailed the intended use of proceeds, outlined the structure of the offering, and explained how to participate. Additionally, CEO Bent Frandsen has recently delivered significant presentations at

YIT selected as partner for the renovation of the Aleksanteri School in Tampere

YIT Corporation Press Release 18 June 2024 at 00:00 p.m.YIT has been selected as a project management contractor for the renovation project of the Aleksanteri School in Tampere, in addition to which YIT will act as main constructor for the project. The City of Tampere is the commissioner of the project. The project is implemented as a goal- and ceiling-priced cooperative project management contract, in which the project management contractor acts as the main constructor of the project. The cost estimate determined by the client for the project management contract is approximately EUR 20

theHunter: Call of the Wild’s “Sundarpatan Nepal Hunting Reserve” DLC Out Now on PlayStation, Xbox & PC

Expansive Worlds’ open-world fishing game Call of the Wild: The Angler also receives a new DLC & content update today STOCKHOLM – June 18, 2024 – Expansive Worlds, a creative division within Avalanche Studios Group, is excited today to release theHunter: Call of the Wild’s newest DLC, the “Sundarpatan Nepal Hunting Reserve,” on PlayStation, Xbox, and PC via Steam, the Epic Games Store and Microsoft Store. Available for $11.99/€11.79, with an additional 20% discount offered across all storefronts through June 24, this new location adds three sprawling regions to the acclaimed

SOFTSWISS Turns On Red Light at iGB L!VE 2024

SOFTSWISS, a global tech provider with over 15 years of experience in iGaming, is set to embark on one of the most anticipated industry events of the year – iGB L!VE.On 17–18 July, iGB L!VE will bring together game providers, operators, affiliates, and tech vendors for a dynamic live iGaming event. Encouraging robust, trust-based partnerships, iGB L!VE offers an opportunity to elevate business development and secure a competitive edge in the industry. The event welcomes around 10,000 gaming and affiliate stakeholders and over 300 exhibitors and sponsors. It unites the iGaming community

Calliditas provides setanaxib patent update

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.”The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expiration date in 2039. Calliditas has corresponding applications and patents in several additional territories around the world,

Change in the holding of Kesko Corporation's treasury shares

Today a total of 17,100 B shares (KESKOB) have been returned to Kesko Corporation without consideration in accordance with the terms and conditions of Kesko's share-based commitment and incentive plan PSP 2021-2024. The shares had initially been granted to a person included in the target group of the 2021-2022 performance period of the plan. Following the return of the shares, Kesko holds 2,122,782 of its own B shares as treasury shares. Further information is available from Matti Mettälä, Executive Vice President, tel. +358 105 322 200. Kesko Corporation DISTRIBUTIONNasdaq

Clas Ohlson is now back in central Helsingborg

Clas Ohlson's new store on Kullagatan in Helsingborg in Sweden is now open, marking the company's return to the city centre. There was significant interest when the store opened on Tuesday morning."We know we are highly appreciated in Helsingborg. It feels fantastic to be able to return to the city centre after four years. With our two stores, it will be convenient for the people of Helsingborg to find what they need for their home fixing," says Andreas Helgesson, Country Operations Manager. Clas Ohlson's previous store in central Helsingborg closed in 2020, and since then, Clas Ohlson

BioStock: BrainCool’s new CEO on his visions for the company

BrainCool has strong momentum right now. Karolinska Institutet has initiated patient recruitment for a cardiac arrest study with the company’s device RhinoChill, and a recently completed rights issue was subscribed to a total of 171 per cent. BioStock contacted the new CEO Jon Berg for a status update and to learn more about his visions for the company.– BrainCool is in an exciting phase and, we believe there is a great market potential and global demand for our cooling devices, says Berg.Read the full interview with Jon Berg at biostock.se: https://www.biostock.se/en/2024/06/

Raisio plc: Announcement of conveyance of own shares

Raisio plc Stock Exchange Release, 18 June 2024   ANNOUNCEMENT OF CONVEYANCE OF OWN SHARES   In April, 2024, Raisio plc’s Annual General Meeting decided that of the monthly reward of the Chairman and members of the Board, approximately 20% shall be paid by distributing shares held by the company and approximately 80% in cash. Rewards shall be paid in two equal lots during the term in June and in December.   Raisio plc has assigned a total of 11,485 free shares (RAIVV) on June 18, 2024 (other conveyance) as a reward to the Chairman and members of the Board for their

Finnair completes rollout of its €200 million new long-haul cabin

This marks the airline’s ultimate investment in customer experience    Finnair has successfully completed the rollout of its new 200 million euro long-haul cabin renewal, with all long-haul aircraft now refurbished.  The project included the launch of an entirely new Business Class seat, a brand-new Premium Economy cabin, and a refreshed Economy Class, giving customers the ultimate onboard experience.  The state-of-the-art cabin was first launched in 2022, and within the space of two years, has been rolled out to the airline’s entire long-haul fleet of A350s and A330s. Customers

Resolutions of Citycon Oyj’s Extraordinary General Meeting

CITYCON OYJ   Stock Exchange Release   18 June 2024 at 11:50 hrsCitycon Oyj’s Extraordinary General Meeting took place today, 18 June 2024.  The Extraordinary General Meeting was held without a meeting venue using remote connection in real time, in accordance with Section 11 of the Articles of Association of the Company and Chapter 5, Section 16 Subsection 3 of the Finnish Limited Liability Companies Act.Based on the Board of Directors’ proposal, the General Meeting resolved that the net amount of the annual fees of the members of the Board of Directors and the Chairmen of the Board of

Gaming Innovation Group rebrands GiG Media to Gentoo Media

Gaming Innovation Group Inc. (GiG), a leader in digital marketing and media within the online gaming sector, today announced that GiG Media will be rebranding to Gentoo Media. The rebranding comes ahead of the planned split of the Company in Q3 2024 as previously announced. The change reflects the Company’s ongoing commitment to growing the business and building on the successful track record as a leading affiliate in the iGaming industry.  The new company name Gentoo Media pays a tribute to GiG Media's Rebel Penguin heritage, as the Gentoo is an Antarctic penguin species known for

Piceasoft’s new AI-powered self-service promotes mobile device circularity by bringing troubleshooting assistant to your pocket

The addition of new AI-powered self-service features to Piceasoft’s mobile device circularity platform allows consumers to easily and accurately assess the condition of their phone at home or on the move. Diagnostics, troubleshooting, and issue resolutions are provided with AI assistance, along with recommendations for additional services like trade-ins or repairs, as a first-of-its-kind solution to extend device lifecycles.TAMPERE, Finland (June 18th, 2024) Piceasoft , Europe's leading provider of mobile device lifecycle solutions, has expanded its Picea® Online

TOMRA: Restated financial statements in EUR

As announced on 26 April 2024, TOMRA will change its presentation currency and start reporting in EUR from the second quarter 2024. This will better reflect the underlying performance in the business and reduce currency volatility in reported numbers. The Statement of financial position and the Profit and loss statement have been restated for each quarter starting 1 January 2019 to 31 March 2024. Assets and liabilities in non-EUR currencies are translated into EUR at the closing exchange rates on the relevant balance sheet date. For 2023 and 2024, non-EUR income and expenditure are

RUFF Golf launches in Switzerland - Five new locations opening soon

The Swedish indoor golf concept RUFF is being launched in Switzerland. The first facility is scheduled to be completed by the end of 2024. In total, there are plans to open five RUFF sites in Switzerland by Markus Gaggl, who now owns the master franchise rights for the entire DACH region. RUFF Golf has sold the master franchise rights for Switzerland to Austrian Markus Gaggl, meaning he takes over the role of franchisor in the area. He already owns master franchise rights for Austria and Germany, which means that he now owns the rights to the entire DACH region. Alex Bengtsson,

Listing prospectus for YIT’s EUR 100 million secured green notes is available and the amendments to the terms of EUR 100 million green notes 2026 have become effective

YIT Corporation Stock Exchange Release 18 June 2024 at 11:30 a.m.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR SUCH OTHER COUNTRIES OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE OFFERING OF THE NEW NOTES OR THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Listing prospectus for YIT’s EUR 100 million secured green notes is available and the amendments to the terms of EUR 100 million green notes 2026 have become effective

Cereno Scientific granted approval from EMA to initiate first-in-human Phase I trial with novel epigenetic HDAC inhibitor, CS014

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Clinical Trial Application (CTA) for a first-in-human, Phase I trial of novel histone deacetylase inhibitor (HDACi) drug candidate CS014, has been approved by the European Medicines Agency.“Progressing CS014 from preclinical to a clinical stage marks a major achievement of our R&D Team. We look forward to exploring the future treatment possibilities based on the existing properties of the drug”, said Dr. Rahul Agrawal,

There are no items matching the current filter
There are no more items matching the current filter
Back to top